Management Team

Dr Greg van Wyk

Dr Greg Van Wyk

Chief Executive Officer & Chief Medical Officer

Greg graduated as a medical doctor, from the University of the Witwatersrand, in 2001 and worked clinically, in hospitals and in GP practice, for 5 years prior to moving into pharmaceutical medicine. Prior to joining Noxopharm, he enjoyed an 11-year career with Eli Lilly during which he led large, diverse medical teams across Australasia and North-western Europe and worked across a range of therapeutic areas, on medicines in all stages of the product Lifecyle.

In both clinical and commercial contexts, Greg is a strategic thinker who is focused on achieving valued outcomes for the multitude of stakeholders engaged with the pharmaceutical industry. He enjoys research design and analysis and he enjoys continuous learning.

Greg has postgraduate degrees in management and economics and is passionate about the healthcare economy and the role of technology in extending and enhancing people's lives. Greg is also a non-executive director of ADHD Australia, a not for profit organisation aiming to make Australia a better place for people affected by ADHD.

Jeanette Bell

Jeanette Bell

Chief Operating Officer

BMedSc  MScM

Jeanette Bell has over 30 years' experience in the health-care sector, including a 15-year career with Eli Lilly Pharmaceuticals. Jeanette's experience spans Clinical Operations, Medical Operations, Sales, Medical Affairs, PMO leadership, Six Sigma, Customer Service and Marketing settings. During her diverse career, Jeanette has worked in leadership roles in Europe, Asia Pacific and Japan. The scope of work in AP involved co-developing the strategy and operations plan for Clinical Development initiatives in China, to support the delivery of registration studies in emerging markets.

Having also worked across several therapeutic areas and clinical development phases, and with first-hand experience in the commercial aspects of biotech, Jeanette understands the importance of a robust operations platform to accelerate innovative medicines to market. With this, she developed a Launch Excellence Model to synchronise teams in the delivery of the pipeline portfolio - from pre-clinical to commercial launch. In terms of the Customer Experience, she facilitated the delivery of the first digital Medical Information platform to support Australian and New Zealand Health Care Professionals and Patients - providing speedy access to medical information services.

Jeanette holds Bachelor of Medical Science, and Master of Science Management degree and is finalising a PhD in Computer Science - where her ethnographic research is grounded in Human-Computer Interaction; looking at how digital technologies can support individuals living with younger onset dementia.

Shawn Van Boheemen

Shawn Van Boheemen

Chief Financial Officer

BBus MCom, FCPA JP

Shawn has 30 years' experience in commercial finance leadership positions across a range of manufacturing, service based and financial services industries. He has worked in senior financial positions for a number of both Australian and multinational organisations, including Covance, Unomedical, M.D. Sass and New York Life Insurance. Shawn has a Bachelor of Business Degree in Accounting and Commercial Law, a Master of Commerce Degree with a major in Accounting, is a Fellow of the Australian Society of Certified Practising Accountants and Justice of the Peace in NSW.  Shawn has experience in the contract research and medical devices industries, along with printing/packaging, software and investment management.  His responsibilities have included a number of company secretarial positions, head of compliance, head of information technology, administration and human resources, warehousing and inventory management.

Shawn has experience with both Australian ASX and ASIC reporting, SEC reporting in the U.S., compliance and regulatory affairs matters, intellectual property protection and regulatory and financial reporting both in Australia and the U.S. He spent three years in a global software company as an analyst and Asia Pacific business development manager to further broaden his commercial skillset. He joined Noxopharm Limited in March 2019 and brings a wide range of commercial and financial skills to the organisation.

Gisela Mautner

Dr Gisela Mautner

Global Medical Director

MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia)

Dr Mautner brings a wealth of experience to her role as Global Medical Director, having held medical leadership roles in the pharma and biotech industry in the USA, Europe and Australia.  As a medical doctor, she is dedicated to making the lives of patients better, and as an industry advocate, she is excited by new developments in treatments that provide new hope to many people. 

In her early career she was a research scientist at the National Institutes of Health (NIH) in Bethesda, MD, USA and at the Kyoto Prefectural University in Kyoto, Japan. She transitioned to the pharma industry to focus on taking new drugs out of the lab and making them widely available to patients.  She has had many successes launching new products for Merck (MSD), Bayer and Amgen. She is proud of her leadership role in one of the most successful drug launches in Australia.

For the last decade her passion has been new therapies in oncology. Her interests encompass small molecules, biologics, gene-modified viruses and radiopharmaceuticals for many different cancer types and from early to late stage disease. She fuels her passion with the knowledge that her efforts improve the life of patients on a daily basis.  Balancing patient care and commercial interests has been part of her responsibilities as the medical lead throughout most of her career as well as directing the medical strategies and operations, budget management, compliance and staff performance in Medical Affairs Departments of multinational companies.

Dr Mautner has built and nurtured a broad network of medical doctors, especially oncologists in Australia and in the USA.  In addition, she is extensively connected to pharmaceutical professionals in Australia as well as in the USA through her work as the VP of the Australian Association for medical and scientific Professionals in the Pharmaceutical industry (APPA) which has recently entered into a partnership with the US based Medical Affairs Professional Society (MAPS).

Having lived and worked in several countries, Dr Mautner is attuned to not only the commercial but also to cultural implications of launching new drugs in foreign territories. As Noxopharm negotiates its global journey, Dr Mautner’s language skills will be invaluable She is fluent in English and German and has intermediary skills in Japanese and French.

John Wilkinson

Dr John Wilkinson

Chief Scientific Officer

John brings over 30 years of experience from both pharmaceutical and research settings in Australia and the United Kingdom, with a focus on the development of small molecules to target viruses and cancer.  John graduated from the University of Portsmouth (BSc Hons) in 1988 and has a PhD in HIV-1 Immunovirology from the University of NSW.  His research interests include Drug Development, Virology, Oncology and Immunology, translating novel laboratory findings into human clinical trials that have previously resulted in numerous peer-reviewed publications.  Prior to joining Noxopharm, John was the Chief Scientific Officer at Biotron Limited, where he was responsible for the oversight of Biotron's antiviral programs and instrumental in the HIV-1 clinical programs.  At Noxopharm, John will manage the scientific, research and technological operations of the company, help set company research and scientific priorities that align with the company's mission and vision.

Olivier Laczka

Business Development Director

PhD  

Dr Laczka obtained a PhD in Biotechnology from the Autonomous University of Barcelona, Spain, in 2009, after completing a master’s degree in applied biotechnology and microbiology and a bachelor’s degree in biological sciences in France. For the first part of his career, Olivier conducted research as an academic, in Spain and Australia, where he was able to successfully develop diagnostic tools toward a wide range of applications, going from medical and food diagnostics to both terrestrial and marine monitoring devices, generating over 25 peer-reviewed research articles and a patent. In 2012, he was awarded the prestigious University of Technology Sydney (UTS) Vice Chancellor’s Postdoctoral Research Fellowship, which enabled him to carry out extensive independent research on the development of novel methods toward the detection of human pathogens.

Dr Laczka’s expertise covers an extensive range of technical skills in microscopy, chemical, electrochemical and optical methods, microbiology, biochemistry, immunology, and molecular biology. In 2015, he joined the Biopharmaceutical industry as a senior research scientist, where he successfully managed and completed therapeutic drug development projects within GLP and cGMP environments, following the current regulatory requirements for early stages of drug development. Throughout his career, Olivier has developed an extensive experience in people and project management, as well as interacting with academic, government, and private entities or individuals, at the international level. His scientific writing experience has also allowed him to attract significant amounts of research funding over the years, through collaborations and partnerships with private entities and government organizations.

 

Karen Thomson

General Manager

Karen joined Noxopharm in May 2017. She is an accomplished and results- oriented Customer Service Professional with 20+ years’ experience in delivery of high value and in-scope service (projects/programs) for large Corporations, previously working as an accomplished Senior IT Service & Project Delivery Professional in ICT sector.

Karen is a passionate about leading organisational change and has a deep expertise across Business Consulting, Technology, Operations, Human Resources, Vendor relationships, Risk Management, Service Delivery and contract management.